| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Protein p53 | 7 | 2026 | 463 | 3.270 |
Why?
|
| Lymphoma, B-Cell | 6 | 2023 | 110 | 2.850 |
Why?
|
| Hodgkin Disease | 12 | 2024 | 144 | 2.810 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 13 | 2025 | 196 | 2.640 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 5 | 2023 | 34 | 1.810 |
Why?
|
| Mutation | 12 | 2026 | 4428 | 1.580 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2026 | 386 | 1.420 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2024 | 150 | 1.130 |
Why?
|
| Biomarkers, Tumor | 9 | 2025 | 1775 | 1.060 |
Why?
|
| Lymphoproliferative Disorders | 4 | 2023 | 105 | 1.000 |
Why?
|
| Hematologic Neoplasms | 3 | 2026 | 383 | 0.980 |
Why?
|
| Bone Marrow | 4 | 2022 | 421 | 0.950 |
Why?
|
| Chromosome Aberrations | 2 | 2026 | 353 | 0.910 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2026 | 113 | 0.900 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2017 | 25 | 0.900 |
Why?
|
| Lymphoma | 2 | 2026 | 255 | 0.870 |
Why?
|
| Mediastinal Neoplasms | 2 | 2022 | 41 | 0.870 |
Why?
|
| Prognosis | 14 | 2026 | 4126 | 0.840 |
Why?
|
| 5-Methylcytosine | 2 | 2022 | 134 | 0.790 |
Why?
|
| Humans | 80 | 2026 | 98362 | 0.760 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2023 | 212 | 0.750 |
Why?
|
| Aged, 80 and over | 17 | 2026 | 7418 | 0.740 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2022 | 28 | 0.730 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2022 | 46 | 0.720 |
Why?
|
| Middle Aged | 38 | 2026 | 29532 | 0.700 |
Why?
|
| Epstein-Barr Virus Infections | 5 | 2019 | 67 | 0.700 |
Why?
|
| Lymphoma, T-Cell | 1 | 2022 | 60 | 0.690 |
Why?
|
| Aged | 33 | 2026 | 21844 | 0.680 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2021 | 45 | 0.670 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2020 | 6 | 0.650 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2017 | 177 | 0.640 |
Why?
|
| Adult | 33 | 2026 | 29587 | 0.620 |
Why?
|
| STAT6 Transcription Factor | 1 | 2019 | 32 | 0.610 |
Why?
|
| Leukemia | 1 | 2022 | 309 | 0.610 |
Why?
|
| Bone Marrow Cells | 3 | 2019 | 270 | 0.580 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2025 | 850 | 0.570 |
Why?
|
| Female | 41 | 2026 | 51756 | 0.560 |
Why?
|
| Male | 43 | 2026 | 47257 | 0.560 |
Why?
|
| Reed-Sternberg Cells | 3 | 2024 | 4 | 0.530 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 262 | 0.520 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 1334 | 0.490 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 111 | 0.490 |
Why?
|
| Erythrocyte Aggregation | 1 | 2016 | 4 | 0.480 |
Why?
|
| Infectious Mononucleosis | 1 | 2016 | 6 | 0.480 |
Why?
|
| Diagnosis, Differential | 9 | 2019 | 1570 | 0.470 |
Why?
|
| Adenocarcinoma | 3 | 2008 | 1214 | 0.470 |
Why?
|
| Histiocytosis, Sinus | 2 | 2019 | 17 | 0.470 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2025 | 444 | 0.460 |
Why?
|
| Lymphocytes | 3 | 2023 | 461 | 0.460 |
Why?
|
| Pathology, Clinical | 2 | 2025 | 39 | 0.450 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2019 | 453 | 0.430 |
Why?
|
| Piperidines | 4 | 2021 | 176 | 0.420 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 480 | 0.410 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2013 | 7 | 0.410 |
Why?
|
| CD11c Antigen | 1 | 2013 | 21 | 0.400 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2013 | 29 | 0.400 |
Why?
|
| Cytoplasmic Granules | 1 | 2013 | 97 | 0.390 |
Why?
|
| Antigens, CD | 2 | 2013 | 484 | 0.390 |
Why?
|
| Herpesvirus 8, Human | 1 | 2013 | 11 | 0.390 |
Why?
|
| Castleman Disease | 1 | 2013 | 11 | 0.390 |
Why?
|
| Sarcoma, Kaposi | 1 | 2013 | 17 | 0.390 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2013 | 19 | 0.390 |
Why?
|
| Prostatic Neoplasms | 4 | 2008 | 1842 | 0.380 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 49 | 0.380 |
Why?
|
| Neoplasm Staging | 7 | 2024 | 2085 | 0.370 |
Why?
|
| Down-Regulation | 2 | 2022 | 529 | 0.370 |
Why?
|
| Immunohistochemistry | 9 | 2022 | 1817 | 0.370 |
Why?
|
| B-Lymphocytes | 5 | 2023 | 731 | 0.370 |
Why?
|
| Monocytes | 1 | 2013 | 220 | 0.360 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2011 | 4 | 0.350 |
Why?
|
| Integrin alpha Chains | 1 | 2011 | 21 | 0.350 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2011 | 73 | 0.350 |
Why?
|
| Breast Neoplasms | 1 | 2026 | 3285 | 0.350 |
Why?
|
| Lewis X Antigen | 1 | 2011 | 9 | 0.340 |
Why?
|
| Fucosyltransferases | 1 | 2011 | 9 | 0.340 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2011 | 15 | 0.330 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2023 | 201 | 0.330 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2026 | 977 | 0.330 |
Why?
|
| Immunophenotyping | 5 | 2025 | 228 | 0.330 |
Why?
|
| Sclerosis | 1 | 2010 | 30 | 0.330 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2010 | 23 | 0.320 |
Why?
|
| Dura Mater | 1 | 2010 | 46 | 0.320 |
Why?
|
| Autoimmune Lymphoproliferative Syndrome | 1 | 2010 | 2 | 0.320 |
Why?
|
| Histiocytic Sarcoma | 1 | 2010 | 7 | 0.320 |
Why?
|
| Image Cytometry | 2 | 2007 | 10 | 0.310 |
Why?
|
| Meningeal Neoplasms | 1 | 2010 | 79 | 0.310 |
Why?
|
| Flow Cytometry | 5 | 2024 | 722 | 0.300 |
Why?
|
| Clone Cells | 2 | 2025 | 223 | 0.300 |
Why?
|
| Adolescent | 13 | 2025 | 10137 | 0.290 |
Why?
|
| Pyrimidines | 3 | 2018 | 415 | 0.290 |
Why?
|
| Neoplasms | 2 | 2020 | 3348 | 0.290 |
Why?
|
| DNA, Neoplasm | 4 | 2013 | 267 | 0.280 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2023 | 150 | 0.270 |
Why?
|
| Neoplasm Proteins | 3 | 2019 | 553 | 0.270 |
Why?
|
| Aneuploidy | 2 | 2007 | 60 | 0.270 |
Why?
|
| Melanoma | 2 | 2024 | 524 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2023 | 671 | 0.260 |
Why?
|
| Young Adult | 14 | 2025 | 7568 | 0.260 |
Why?
|
| Lymph Nodes | 3 | 2020 | 563 | 0.250 |
Why?
|
| Skin Neoplasms | 2 | 2024 | 638 | 0.250 |
Why?
|
| Pyrazoles | 2 | 2018 | 160 | 0.240 |
Why?
|
| Ploidies | 1 | 2006 | 39 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 1539 | 0.240 |
Why?
|
| Logistic Models | 2 | 2007 | 1276 | 0.240 |
Why?
|
| Phenotype | 2 | 2023 | 2667 | 0.230 |
Why?
|
| Medical Laboratory Personnel | 1 | 2025 | 4 | 0.230 |
Why?
|
| Flavonoids | 1 | 2006 | 86 | 0.230 |
Why?
|
| Observer Variation | 2 | 2007 | 579 | 0.230 |
Why?
|
| Disease-Free Survival | 2 | 2026 | 1195 | 0.230 |
Why?
|
| Tumor Microenvironment | 3 | 2025 | 621 | 0.230 |
Why?
|
| Plasma Cells | 2 | 2019 | 91 | 0.220 |
Why?
|
| Karyotyping | 1 | 2025 | 220 | 0.220 |
Why?
|
| Statistics as Topic | 1 | 2006 | 229 | 0.220 |
Why?
|
| Hematologic Diseases | 1 | 2025 | 77 | 0.220 |
Why?
|
| Adenine | 3 | 2021 | 101 | 0.220 |
Why?
|
| Erythroblasts | 1 | 2025 | 27 | 0.220 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2024 | 464 | 0.220 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 2381 | 0.220 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2025 | 37 | 0.220 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2024 | 24 | 0.210 |
Why?
|
| Biopsy | 2 | 2019 | 1225 | 0.210 |
Why?
|
| Antibodies, Bispecific | 1 | 2025 | 51 | 0.210 |
Why?
|
| Oxidative Phosphorylation | 1 | 2024 | 61 | 0.210 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2024 | 88 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2020 | 110 | 0.200 |
Why?
|
| Biomarkers | 3 | 2023 | 2021 | 0.200 |
Why?
|
| Incidental Findings | 1 | 2024 | 100 | 0.200 |
Why?
|
| Cystic Fibrosis | 1 | 2025 | 124 | 0.200 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2023 | 5 | 0.200 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 420 | 0.200 |
Why?
|
| In Situ Hybridization | 4 | 2013 | 306 | 0.190 |
Why?
|
| Sarcoma | 1 | 2025 | 222 | 0.190 |
Why?
|
| Dermatitis | 1 | 2023 | 34 | 0.190 |
Why?
|
| Exanthema | 1 | 2023 | 43 | 0.190 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 700 | 0.180 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 68 | 0.180 |
Why?
|
| Apoptosis | 2 | 2023 | 1752 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 244 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2024 | 159 | 0.180 |
Why?
|
| Cyclin D1 | 2 | 2016 | 86 | 0.180 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 1785 | 0.180 |
Why?
|
| Neoplasm, Residual | 2 | 2021 | 206 | 0.170 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 667 | 0.170 |
Why?
|
| Cell Proliferation | 2 | 2023 | 1791 | 0.170 |
Why?
|
| Cell Nucleus | 3 | 2008 | 615 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 261 | 0.160 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 332 | 0.160 |
Why?
|
| Cell Lineage | 1 | 2022 | 332 | 0.160 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 244 | 0.160 |
Why?
|
| Spleen | 2 | 2013 | 376 | 0.160 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 380 | 0.160 |
Why?
|
| Retrospective Studies | 6 | 2026 | 11039 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2020 | 22 | 0.160 |
Why?
|
| Chromothripsis | 1 | 2020 | 9 | 0.160 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2021 | 112 | 0.160 |
Why?
|
| Mitochondria | 1 | 2024 | 650 | 0.160 |
Why?
|
| Combined Modality Therapy | 4 | 2015 | 1752 | 0.160 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2020 | 12 | 0.160 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2019 | 4 | 0.150 |
Why?
|
| Lung Transplantation | 1 | 2025 | 390 | 0.150 |
Why?
|
| Mastitis | 1 | 2019 | 6 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 2661 | 0.150 |
Why?
|
| Biopsy, Needle | 3 | 2012 | 226 | 0.150 |
Why?
|
| Sezary Syndrome | 1 | 2019 | 12 | 0.150 |
Why?
|
| Genomic Instability | 1 | 2020 | 90 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2009 | 403 | 0.150 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2019 | 48 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2025 | 867 | 0.150 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2019 | 31 | 0.150 |
Why?
|
| Mycosis Fungoides | 1 | 2019 | 30 | 0.150 |
Why?
|
| Ki-1 Antigen | 1 | 2019 | 19 | 0.150 |
Why?
|
| Breast Diseases | 1 | 2019 | 101 | 0.150 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 53 | 0.140 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 20 | 0.140 |
Why?
|
| Thymus Neoplasms | 1 | 2019 | 48 | 0.140 |
Why?
|
| Graft Rejection | 1 | 2025 | 1186 | 0.140 |
Why?
|
| Sulfonamides | 1 | 2021 | 351 | 0.140 |
Why?
|
| Inflammation | 1 | 2025 | 1133 | 0.140 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2018 | 45 | 0.140 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 116 | 0.130 |
Why?
|
| Treatment Outcome | 6 | 2024 | 9770 | 0.130 |
Why?
|
| Breast | 1 | 2019 | 316 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 589 | 0.130 |
Why?
|
| Muscle, Smooth | 2 | 2009 | 299 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2009 | 158 | 0.120 |
Why?
|
| CD5 Antigens | 1 | 2016 | 13 | 0.120 |
Why?
|
| Coombs Test | 1 | 2016 | 9 | 0.120 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 252 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2017 | 506 | 0.120 |
Why?
|
| Burkitt Lymphoma | 1 | 2015 | 32 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 305 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2019 | 369 | 0.110 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2023 | 44 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 291 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 1568 | 0.100 |
Why?
|
| Chediak-Higashi Syndrome | 1 | 2013 | 2 | 0.100 |
Why?
|
| Leukocytosis | 1 | 2013 | 15 | 0.100 |
Why?
|
| Blood Cell Count | 1 | 2013 | 67 | 0.100 |
Why?
|
| HLA-DR Antigens | 1 | 2013 | 58 | 0.100 |
Why?
|
| Data Mining | 1 | 2013 | 45 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 894 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2013 | 3227 | 0.100 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 9 | 0.100 |
Why?
|
| Laser Capture Microdissection | 1 | 2013 | 20 | 0.100 |
Why?
|
| Survival Rate | 2 | 2019 | 2050 | 0.100 |
Why?
|
| Carcinoma | 2 | 2024 | 442 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 291 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 889 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2023 | 2896 | 0.090 |
Why?
|
| Viral Load | 1 | 2013 | 162 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2010 | 100 | 0.090 |
Why?
|
| DNA, Viral | 1 | 2013 | 238 | 0.090 |
Why?
|
| Gene Rearrangement | 1 | 2013 | 175 | 0.090 |
Why?
|
| Pseudolymphoma | 1 | 2011 | 7 | 0.080 |
Why?
|
| Cell Separation | 1 | 2011 | 201 | 0.080 |
Why?
|
| Mice | 5 | 2024 | 12735 | 0.080 |
Why?
|
| Mucous Membrane | 2 | 2009 | 83 | 0.080 |
Why?
|
| Urothelium | 2 | 2009 | 67 | 0.080 |
Why?
|
| Oral Ulcer | 1 | 2010 | 3 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 1 | 2011 | 127 | 0.080 |
Why?
|
| Skin Diseases, Infectious | 1 | 2010 | 8 | 0.080 |
Why?
|
| Skin Ulcer | 1 | 2010 | 28 | 0.080 |
Why?
|
| fas Receptor | 1 | 2010 | 73 | 0.080 |
Why?
|
| Rituximab | 2 | 2023 | 136 | 0.080 |
Why?
|
| Piperazines | 1 | 2012 | 307 | 0.080 |
Why?
|
| Recurrence | 3 | 2023 | 1264 | 0.080 |
Why?
|
| Family Health | 1 | 2010 | 157 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2010 | 295 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2010 | 286 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2013 | 1100 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2010 | 156 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2010 | 309 | 0.070 |
Why?
|
| Myoepithelioma | 1 | 2008 | 15 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2013 | 2009 | 0.070 |
Why?
|
| Parotid Neoplasms | 1 | 2008 | 22 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2009 | 131 | 0.070 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2007 | 7 | 0.070 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2008 | 37 | 0.070 |
Why?
|
| Karyotype | 2 | 2019 | 34 | 0.070 |
Why?
|
| Cytoskeletal Proteins | 1 | 2009 | 225 | 0.070 |
Why?
|
| Discriminant Analysis | 1 | 2007 | 64 | 0.070 |
Why?
|
| Sarcoma, Ewing | 1 | 2007 | 42 | 0.070 |
Why?
|
| Child | 2 | 2025 | 7745 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2008 | 578 | 0.060 |
Why?
|
| Sarcoma, Synovial | 1 | 2007 | 20 | 0.060 |
Why?
|
| Infant | 2 | 2025 | 3358 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2010 | 386 | 0.060 |
Why?
|
| Antibodies | 1 | 2009 | 349 | 0.060 |
Why?
|
| Vaginal Smears | 1 | 2007 | 71 | 0.060 |
Why?
|
| Histological Techniques | 1 | 2006 | 33 | 0.060 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2007 | 36 | 0.060 |
Why?
|
| Photometry | 1 | 2006 | 12 | 0.060 |
Why?
|
| Germ-Line Mutation | 1 | 2010 | 402 | 0.060 |
Why?
|
| Genomics | 2 | 2025 | 903 | 0.060 |
Why?
|
| Cytogenetic Analysis | 1 | 2006 | 70 | 0.060 |
Why?
|
| Testicular Neoplasms | 1 | 2007 | 126 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2006 | 35 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2007 | 126 | 0.060 |
Why?
|
| Papillomaviridae | 1 | 2007 | 184 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2023 | 3633 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2006 | 161 | 0.060 |
Why?
|
| Retinoblastoma Protein | 1 | 2006 | 68 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2006 | 62 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2006 | 471 | 0.060 |
Why?
|
| Animals | 5 | 2024 | 28981 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 2007 | 262 | 0.060 |
Why?
|
| United States | 3 | 2025 | 8258 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 4044 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 356 | 0.060 |
Why?
|
| Pathologists | 1 | 2025 | 44 | 0.060 |
Why?
|
| Cytological Techniques | 1 | 2005 | 30 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 1019 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2025 | 90 | 0.050 |
Why?
|
| Sentinel Lymph Node | 1 | 2024 | 23 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 639 | 0.050 |
Why?
|
| India | 1 | 2005 | 148 | 0.050 |
Why?
|
| Eosinophils | 1 | 2025 | 196 | 0.050 |
Why?
|
| ROC Curve | 1 | 2006 | 793 | 0.050 |
Why?
|
| Allografts | 1 | 2025 | 220 | 0.050 |
Why?
|
| Vincristine | 1 | 2023 | 102 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2007 | 602 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2007 | 449 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2023 | 57 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2007 | 311 | 0.050 |
Why?
|
| Neutrophils | 1 | 2025 | 346 | 0.050 |
Why?
|
| Prostatectomy | 1 | 2006 | 491 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2007 | 682 | 0.050 |
Why?
|
| Prednisone | 1 | 2023 | 251 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2024 | 355 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 284 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2023 | 285 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2023 | 143 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2023 | 4817 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 135 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2023 | 205 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2025 | 988 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 335 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 226 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 358 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2024 | 552 | 0.040 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2021 | 106 | 0.040 |
Why?
|
| Emperipolesis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2020 | 110 | 0.040 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2019 | 16 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2020 | 69 | 0.040 |
Why?
|
| Erythroid Cells | 1 | 2019 | 17 | 0.040 |
Why?
|
| Disease Progression | 2 | 2019 | 1615 | 0.040 |
Why?
|
| S100 Proteins | 1 | 2019 | 51 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 2019 | 39 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2007 | 2599 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2021 | 420 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 1304 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 1028 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 127 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 241 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2020 | 216 | 0.040 |
Why?
|
| Tretinoin | 1 | 2019 | 130 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2019 | 121 | 0.040 |
Why?
|
| Immediate-Early Proteins | 1 | 2020 | 160 | 0.040 |
Why?
|
| Benzodioxoles | 1 | 2018 | 15 | 0.040 |
Why?
|
| Fibrosis | 1 | 2019 | 234 | 0.030 |
Why?
|
| Mortality | 1 | 2019 | 159 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 478 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2019 | 161 | 0.030 |
Why?
|
| Purines | 1 | 2018 | 96 | 0.030 |
Why?
|
| Histiocytes | 1 | 2017 | 22 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2025 | 4038 | 0.030 |
Why?
|
| World Health Organization | 2 | 2007 | 125 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 2577 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2548 | 0.030 |
Why?
|
| Time Factors | 1 | 2006 | 5576 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 3032 | 0.030 |
Why?
|
| src Homology Domains | 1 | 2016 | 46 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 559 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 1102 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2019 | 424 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 583 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 554 | 0.030 |
Why?
|
| Risk Factors | 1 | 2025 | 6271 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 1397 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2013 | 107 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1529 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 578 | 0.020 |
Why?
|
| Pancytopenia | 1 | 2012 | 17 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2012 | 128 | 0.020 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2011 | 16 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 1094 | 0.020 |
Why?
|
| Developed Countries | 1 | 2011 | 25 | 0.020 |
Why?
|
| Benzamides | 1 | 2012 | 260 | 0.020 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2010 | 18 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 45 | 0.020 |
Why?
|
| Genes, Immunoglobulin | 1 | 2010 | 62 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2010 | 71 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2009 | 125 | 0.020 |
Why?
|
| Fractures, Compression | 1 | 2007 | 22 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2008 | 276 | 0.020 |
Why?
|
| Pathology | 1 | 2007 | 36 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2007 | 149 | 0.020 |
Why?
|
| Societies, Scientific | 1 | 2007 | 40 | 0.020 |
Why?
|
| Bone Screws | 1 | 2007 | 74 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2007 | 135 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 2007 | 105 | 0.020 |
Why?
|
| Aging | 1 | 2011 | 770 | 0.010 |
Why?
|
| Urology | 1 | 2007 | 144 | 0.010 |
Why?
|
| Age Factors | 1 | 2010 | 1974 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2007 | 376 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2007 | 687 | 0.010 |
Why?
|
| Prostate | 1 | 2006 | 434 | 0.010 |
Why?
|
| Spinal Fusion | 1 | 2007 | 373 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1945 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 1116 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 3612 | 0.010 |
Why?
|